Wall Street brokerages forecast that Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will report $59.56 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Dicerna Pharmaceuticals’ earnings. The highest sales estimate is $76.10 million and the lowest is $49.20 million. Dicerna Pharmaceuticals reported sales of $34.03 million in the same quarter last year, which would suggest a positive year over year growth rate of 75%. The firm is scheduled to issue its next earnings report after the market closes on Thursday, May 6th.

On average, analysts expect that Dicerna Pharmaceuticals will report full year sales of $253.98 million for the current fiscal year, with estimates ranging from $175.00 million to $489.20 million. For the next financial year, analysts anticipate that the firm will post sales of $255.84 million, with estimates ranging from $134.77 million to $314.60 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.60). The business had revenue of $40.96 million during the quarter, compared to analyst estimates of $81.82 million. Dicerna Pharmaceuticals had a negative return on equity of 71.72% and a negative net margin of 88.81%.

A number of brokerages have issued reports on DRNA. The Goldman Sachs Group initiated coverage on Dicerna Pharmaceuticals in a research report on Thursday, April 22nd. They set a “buy” rating and a $48.00 price target for the company. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 11th. Chardan Capital upped their price objective on Dicerna Pharmaceuticals from $25.00 to $34.00 and gave the company a “buy” rating in a report on Monday, March 8th. B. Riley lifted their target price on Dicerna Pharmaceuticals from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, March 1st. Finally, Truist upped their price target on shares of Dicerna Pharmaceuticals from $35.00 to $45.00 in a report on Monday, April 19th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Dicerna Pharmaceuticals currently has an average rating of “Buy” and an average price target of $40.44.

Shares of Dicerna Pharmaceuticals stock traded down $0.53 on Friday, reaching $29.76. 11,295 shares of the company were exchanged, compared to its average volume of 800,119. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -18.81 and a beta of 1.33. Dicerna Pharmaceuticals has a 1-year low of $16.50 and a 1-year high of $32.67. The company’s 50-day moving average is $27.24 and its two-hundred day moving average is $24.75.

In other Dicerna Pharmaceuticals news, insider Regina M. Paglia sold 4,431 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Thursday, April 1st. The stock was sold at an average price of $25.86, for a total transaction of $114,585.66. Following the sale, the insider now directly owns 4,431 shares of the company’s stock, valued at $114,585.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Bob D. Brown sold 8,312 shares of the company’s stock in a transaction that occurred on Wednesday, February 3rd. The shares were sold at an average price of $25.00, for a total value of $207,800.00. Over the last ninety days, insiders sold 43,115 shares of company stock valued at $1,187,629. 11.30% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of the company. Compagnie Lombard Odier SCmA acquired a new position in shares of Dicerna Pharmaceuticals in the 1st quarter worth approximately $13,451,000. Caas Capital Management LP acquired a new position in Dicerna Pharmaceuticals during the 4th quarter worth about $10,790,000. BlackRock Inc. lifted its position in shares of Dicerna Pharmaceuticals by 4.1% during the fourth quarter. BlackRock Inc. now owns 6,034,729 shares of the biopharmaceutical company’s stock worth $132,944,000 after purchasing an additional 235,875 shares in the last quarter. Panagora Asset Management Inc. lifted its position in shares of Dicerna Pharmaceuticals by 314.7% during the fourth quarter. Panagora Asset Management Inc. now owns 300,504 shares of the biopharmaceutical company’s stock worth $6,620,000 after purchasing an additional 228,035 shares in the last quarter. Finally, Silverarc Capital Management LLC bought a new position in Dicerna Pharmaceuticals in the 4th quarter valued at $5,009,000. Institutional investors own 80.64% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain.

Recommended Story: How much can an individual set aside as a catch-up contribution?

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.